Benjamin P. Levy, MD
Clinical trial evidence is building for moving checkpoint blockade immunotherapy forward in the treatment timeline for non–small cell lung cancer (NSCLC), but improving patient selection for these therapies remains a key challenge, according to an OncLive Peer Exchange®
panel of international experts.
Although advancements have reshaped the landscape for metastatic NSCLC, changes in the paradigm for treating patients with locally advanced disease have been slower to develop, noted Benjamin P. Levy, MD, who moderated the panel. “[It’s] a space where we’ve really been begging for new therapies,” he said. “Immunotherapy first landed in the advanced-stage setting in the second line, but it’s being moved up to the first line, and now we’re seeing emerging data with the use of immunotherapy in the locally advanced setting.”
During the Peer Exchange
, which took place during the International Association for the Study of Lung Cancer 19th World Conference on Lung Cancer (WCLC 2018), a panel of thoracic oncology experts from the United States and Europe discussed new checkpoint inhibitor data in the stage III and IV NSCLC setting. The panelists provided insights on how they are using various immunotherapy approaches in their clinical practices to improve patient outcomes.
Treating Stage III NSCLC
... to read the full story